Lundbeck to Present Groundbreaking Movement Disorder Research at MDS® 2026 Conference

Lundbeck's Significant Advances in Movement Disorders Research

H. Lundbeck A/S, a prominent biopharmaceutical company, is set to unveil its innovative research on movement disorders at the International Congress of Parkinson's Disease and Movement Disorders® (MDS) 2026. This prestigious event will take place from October 4 to 8 in Seoul, South Korea. Lundbeck aims to inform the scientific community about its evolving pipeline focused on conditions such as Multiple System Atrophy (MSA) and advanced Parkinson's Disease (PD).

The cornerstone of Lundbeck's presentation will be a late-breaking Phase III oral presentation detailing the MASCOT trial, which investigates amlenetug, an investigational treatment for MSA. This trial, which includes 401 participants diagnosed with clinically probable or established MSA, is designed to evaluate the safety and efficacy of amlenetug compared to a placebo over a 72-week period. MSA is a rare and fast-progressing neurodegenerative disorder, and the results of this groundbreaking study are expected in the third quarter of 2027.

Amlenetug and the MASCOT Trial

The MASCOT trial (NCT06706622) targets individuals with both MSA-C (cerebellar) and MSA-P (parkinsonian) variants, representing a diverse patient population. Lundbeck’s Executive Vice President, Tarek Samad, emphasizes the critical importance of addressing the complexities of movement disorders, stating, "Movement disorders such as MSA and Parkinson's disease remain among the most complex and high-need areas in neuroscience."

With MSA often characterized by severe symptoms like balance issues, speech difficulties, and autonomic disturbances, this trial aims to provide crucial data that could lead to new treatment options for patients suffering from this debilitating condition.

Lundbeck will also share insights into additional scientific research, including analyses that validate the modified Unified Multiple System Atrophy Rating Scale Part I (mUMSARS Part I) as a key clinical endpoint in trials. Their findings highlight the high healthcare burden experienced by MSA patients compared to those with Parkinson's disease, emphasizing a greater healthcare resource utilization and costs associated with MSA.

Parkinson's Disease Research

In a further expansion of their movement disorders program, Lundbeck will present exploratory data for Lu AF28996, a new oral dopamine receptor agonist currently undergoing Phase Ib trials. This innovative treatment aims to improve motor fluctuations and manage levodopa-induced dyskinesia in patients with advanced Parkinson's disease—a progression of the condition that significantly affects quality of life and functional independence.

The Phase Ib trial evaluated the safety and tolerability of Lu AF28996 on a group of advanced PD patients suffering from motor complications. Complementary preclinical studies further demonstrate the drug's potential in reducing dyskinesia within animal models, paving the way for future therapeutic applications in this challenging patient population.

Conclusion

As Lundbeck prepares to showcase its advancements at MDS 2026, the company reiterates its commitment to addressing the substantial unmet needs within the movement disorder landscape. The data presented at this international congress will not only shed light on existing treatment obstacles but also pave the way for promising innovations in the field of neurology. Lundbeck continues to lead the charge in developing effective therapies for neurodegenerative diseases, reflecting a deeper understanding of brain health challenges ahead.

For further details about Lundbeck's presentations at MDS 2026, you may visit their official corporate website or connect via professional networks for continuous updates.